Leptomeningeal carcinomatosis

Cancer Treatment Reviews

Volumn 25, Issue 2, 1999, Pages 103-119

  Grossman, Stuart A ^a   Krabak, Michael J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Breast cancer; Cerebrospinal fluid; CNS cancer; Cytarabine; Intrathecal chemotherapy; Leptomeningeal carcinomatosis; Lung cancer; Melanoma; Meningeal carcinomatosis; Methotrexate; Neoplastic meningitis; Radiation therapy; Thiotepa

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DIAZIQUONE; IMMUNOTOXIN; LIPOSOME; MAFOSFAMIDE; METHOTREXATE; NIMUSTINE; THIOTEPA; TOPOTECAN;

ARACHNOIDITIS; BONE MARROW SUPPRESSION; BRAIN FUNCTION; BREAST CANCER; CANCER INVASION; CANCER RADIOTHERAPY; CARCINOMATOUS MENINGITIS; CEREBROSPINAL FLUID CYTOLOGY; CEREBROSPINAL FLUID FLOW; CLINICAL TRIAL; CONTRAST ENHANCEMENT; EARLY DIAGNOSIS; GENE THERAPY; HEADACHE; HUMAN; HYDROCEPHALUS; INTRAARTERIAL DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; LEPTOMENINX; LEUKOENCEPHALOPATHY; LUMBAR PUNCTURE; LUNG CANCER; MELANOMA; MUCOSA INFLAMMATION; NAUSEA; NERVE FUNCTION; NEUROPATHY; NONHUMAN; PROGNOSIS; RADIOLOGY; REVIEW; SEIZURE; SUBARACHNOID SPACE; SURVIVAL; TREATMENT OUTCOME; VOMITING;

EID: 0033117810     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.1999.0119     Document Type: Review

References (121)

1. Eberth CJ. Zur entwicklung des epitheliomas (cholesteatomas) dur pia under der lungs. Virchow's Arch 1870; 49: 51-63
2. Nugent JL, Bunn PA Jr, Matthews MJ, et al. CNS metastases in small cell bronchogenic carcinoma; Increasing frequency and changing pattern with lengthening survival. Cancer 1979; 44: 1885-1893.
3. Shapiro WR, Posner JB, YUkitaka Y, et al. Treatment of meningeal neoplasms. Cancer Treat Rep 1977; 61: 733-743.
4. Bunn PA, Schein PS, Banks PM. Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: Leukemia revisited. Blood 1976; 47: 3-10.
5. Bigner SH, Johnston WW. The cytopathology of cerebrospinal fluid. II. Metastatic cancer, meningeal carcinomatosis and primary central nervous system neoplasms. Acta Cytol 1981; 25: 461-479.
6. Gonzalez Vitae JC, Garcia Bunuel R. Meningeal carcinomatosis. Cancer 1976; 37: 2906-2911.
7. Boyle R, Thomas M, Adams JH. Diffuse involvement of the leptomeninges by tumor-a clinical and pathological study of 63 cases. Postgrad Med J 1980; 56: 149-158.
8. Little JR, Dale AJ, Okazaki H. Meningeal carcinomatosis. Clinical manifestations. Arch Neurol 1974; 30:138-143
9. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patients. Cancer 1982; 49: 759-772.
10. Glass JP, MelaMed M, Chernik NL, et al. Malignant cells in cerebrospinal fluid (CSF): The meaning of a positive CSF cytology. Neurology 1979; 29:1369-1375.
11. Yap HY, Yap BS, Tashima CK, et al. Meningeal carcinomatosis from breast cancer. Cancer 1978; 42: 283-286.
12. Aroney RS, Dalley DN, Chan WK, et al. Meningeal carcinomatosis in small cell carcinoma of the lung. Am J Med 1981; 71: 26-32.
13. Rosen ST, Aisner J, Makuch RW, et al. Carcinomatous leptomeningitis in small cell lung cancer: A clinicopathologic review of the national cancer institute experience. Medicine (Baltimore) 1982; 61: 45-53.
14. Amer MH, Al Sarraf M, Baker LH, et al. Malignant melanoma and central nervous system metastases. Cancer 1978; 42: 660-668.
15. Ehya H, Hajdu SI, Melamed MR. Cytopathology of nonlymphoreticular neoplasms metastatic to the central nervous system. Acta Cytol 1981; 25: 599-610.
16. Yung WA, Horten BC, Shapiro WR. Meningeal gliomatosis: A review of 12 cases. Ann Neurol 1980; 8: 605-608.
17. Redman BG, Tapazoglou E, AI Sarraf M. Meningeal carcinomatosis in head and neck cancer. Report of six cases and review of the literature. Cancer 1986; 58: 2656-2661.
18. Price RA, Johnson WW. The central nervous system in childhood leukemia. I. The arachnoid. Cancer 1973; 31: 520-533.
19. Azzarelli B, Mirkin LD, Goheen M. The leptomeningeal vein- A site of re-entry of leukemic cells into the systemic circulation. Cancer 1984; 54: 1333-1343.
20. Grain GO, Karr JP. Diffuse leptomeningeal carcinomatosis: Clinical and pathologic characteristics. Neurology 1955; 5: 706-722.
21. Weissman, DW and Grossman, SA. Simultaneous leptomeningeal and intramedullary spinal metastases in small cell lung carcinoma. Med Pediatr Oncol 1986; 14: 54-56.
22. Mackintosh FR, Colby TA, Podolsky WJ. Central nervous system involvement in non-Hodgkin's lymphoma. An analysis of 105 cases. Cancer 1982; 49: 586-595.
23. Norris LK, Grossman SA, Olivi A. Neoplastic meningitis following surgical resection of isolated cerebellar metastases: A potentially preventable complication. J Neuro-Oncol, 1997; 32: 215-223.
24. DeAngelis LM. Current diagnosis and treatment of leptomeningeal metastasis. J Neurooncol. 1998; 38: 245-252.
25. Chamberlain MC. Carcinomatous meningitis. Arch Neurol 1997; 54: 16-17.
26. Jayson GC and Howell A. Carcinomatous meningitis in solid tumors. Ann Oncol 1996; 7: 773-786.
27. BalM M, Hammack J. Leptomeningeal carcinomatosis. Arc Neurol 1996; 53: 626-632.
28. 111Indium-DTPA ventriculography. Am J Med 1982; 73: 641-647.
29. Chamberlain MC, Corey-Bloom J. Leptomeningeal metastases: 111-Indium-DTPA CSF flow studies. Neurol 1991; 41: 1765-1769.
30. Siegal T, Mildworf B, Stein D, Melamed E. Leptomeningeal metastases: Reduction in regional cerebral blood flow and cognitive impairment. Ann Neurol 1985; 17:100-102.
31. Olson ME, Chernik NL, Posner JB. Infiltration of the leptomeninges by systemic cancer. A clinical and pathologic study. Arch Neurol 1974; 30: 122-137.
32. Theodore WH, Gendelman S. Meningeal carcinomatosis. Arch Neurol 1981; 38: 696-699.
33. TwijnstrA A, Ongerboer dr Visser BW, van Zanten AP. Diagnosis of leptomeningeal metastasis. Clin Neurol Neurosurg 1987; 89: 79-85.
34. Kaplan JG, DeSouza TG, Farkash A, et al. Leptomeningeal metastases: Comparison of clinical features and laboratory data of solid tumors, lymphomas, and leukemias. J Neurooncol 1990; 9: 225-229.
35. Reuler JB, Meier D. Leptomeningeal carcinomatosis with normal CSF features. Arch Intern Med 1979; 139: 237-238.
36. Davies SF, Gormus BJ, Yarchoan R. Cryptococcal meningitis with false-positive cytology in the CSF: Use of T-cell rosetting to exclude meningeal lymphoma. JAMA 1978; 239: 2369-2370.
37. Rawlinson DG, Billingham ME, Berry PF. Cytology of the cerebrospinal fluid in patients with Hodgkin's disease or malignant lymphoma. Acta Neuropathol (Berl) 1975; 6: 187-191.
38. Murray JJ, Greco FA, Wolff SN, Hainsworth JD. Neoplastic meningitis. Marked variation of cerebrospinal fluid composition in the absence of extradural block. Am J Med 1978; 75: 289-294.
39. Coakham HB, Kemshead JT. The present role of monoclonal antibodies in the diagnosis and therapy of brain tumours. Wien Klin Wochenschr 1987; 99: 378-378.
40. Kranz BR, Thiel E, Thierfelder S. Immunocytochemical identification of meningeal leukemia and lymphoma: Poly-L-lysine-coated slides permit multimarker analysis even with minute cerebrospinal fluid cell specimens. Blood 1989; 73: 1942-1950.
41. Chamberlain MC. Cytologically negative carcinomatous meningitis: Usefulness of CSF biochemical markers. Neurology 1998; 50: 1173-1175.
42. SChold SC, Wasserstrom WR, Fleischer M, et al. Cerebrospinal fluid biochemical markers of central nervous system metastasis. Ann Neuro 1980; 97-604.
43. Wasserstrom WR, Schwarz MK, Fleisher M, et al. Cerebrospinal fluid biochemical markers in central nervous system tumors: A review. Ann Clin Lab Sci 1981; 11: 239-251.
44. Jacobi C, Reiber H, Felgenhauer K. The clinical relevance of locally produced carcinoembryonic antigen in cerebrospinal fluid. J Neurol 1986; 233: 358-361.
45. Klee GG, Tallman RD, Goellner JR et al. Elevation of carcinoembryonic antigen in cerebrospinal fluid among patients with meningeal carcinomatosis. Mayo Clin Proc 1986; 61: 9-13.
46. Yap BS, Yap HY, Pritsche HA, et al. CSF carcinoembryonic antigen in meningeal carcinomatosis from breast cancer. JAMA 1980; 244: 1601-1603.
47. Shuttleworth E, Allen N. CSF beta-glucuronidase assay in the diagnosis of neoplastic meningitis. Arch Neurol 1980; 37: 684-687.
48. Tallman RD, Kimbrough SM, Obrien JF, et al. Assay for betaglucuronidase in cerebrospinal fluid. Usefulness for the detection of neoplastic meningitis. Mayo Clin Proc 1985; 60: 293-298.
49. Twijnstra A, van Zanten AP, Nooven WJ, et al. Sensitivity and specificity of single and combined tumour markers in the diagnosis of leptomeningeal metastasis from breast cancer. J Neurol Neurosurgery Psychiatry 1986; 49: 1246-1250.
50. Twijnstra A, van Zanten AP, Hart AA, et al. Serial lumbar and ventricle cerebrospinal fluid lactate dehydrogenase activities in patients with leptomeningeal metastases from solid and haematological tumours. J Neurol Neurosurgery Psychoatry 1987; 50: 313-320.
51. Van Zanten AP, Twijnstra A, Ongerboer de Visser BW, et al. Tumour markers in the cerebrospinal fluid of patients with central nervous system metastases from extracranial malignancies. Clin Chim Acta 1988; 175: 157-166.
52. Fleisher M, Wasserstrom WR, Schold SC, et al. Lactic dehydrogenase isoenzymes in the cerebrospinal fluid of patients with systemic cancer. Cancer 1981; 47: 2654-2659.
53. Adachi N. Beta-2-microglobulin levels in the cerebrospinal fluid, their value as a disease marker. Eur Neurol 1991; 31: 181-185.
54. Jeffrey GM, Frampton CM, Legge HM, et al. Cerebrospinal fluid B2-microglobulin levels in meningeal involvement by malignancy. Pathology 1990; 22: 20-23.
55. Krol G, Sze G, Malkin N\M et al. MR of cranial and spinal meningeal carcinomatosis: Comparison with CT and myelography. AJR 1988; 151: 583-588.
56. Pederson AG, Paulson OB, Gyldensted C. Metrizamide myelography in patients with small cell carcinoma of the lung suspected of meningeal carcinomatosis. J Neurooncol 1985; 3: 85-89.
57. Chamberlain MC, Sandy AD, Press GA. Leptomeningeal metastasis: A comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology 1990; 40: 435-438.
58. Sze G, SoletSky S, BronEn E, et al. MR imaging of the cranial meninges with emphasis on contrast enhancement and meningeal carcinomatosis. AJNR 1989; 10: 965-975.
59. Grossman SA, Moynihan TJ. Neoplastic meningitis. Neurology Clinics of North America 1991; 9: 843-856.
60. Chamberlain MC and Kormanik PR. Carcinomatous meningitis secondary to breast cancer: Predictors of response to combined modality therapy. J Neurooncol 1997; 35: 55-64.
61. Shapiro WR, Young DF, Mehta BM. Methotrexate: Distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975; 293: 161-166.
62. Bleyer WA, Poplack DG. Intraventricular versus intralumbar methotrexate for CNS leukemia: Prolonged remission with the Ommaya reservoir. Med Pediatr Oncol 1979; 6: 207-213.
63. Haghbin M, Galicich JH. Use of the Ommaya reservoir in prevention and treatment of CNS leukemia. Am J Pediatr Hematol Oncol 1979; 1: 111-117.
64. Rogers LR, Duchesneau PM, Nunez C, et al. Comparison of cisternal and lumbar CSF examination in leptomeningeal metastasis. Neurol 1992; 42:1239-1241.
65. 111Indium-DTPA ventriculography. Am J Med 1982; 73: 641-647.
66. Glantz MJ, Hall WA, Cole BF, et al. Diagnosis, management of, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 1995; 75: 2919-2931.
67. Bleyer WA, Drake JC, Chabner BA. Neurotoxicity and elevated cerebrospinal fluid methotrexate concentration in meningeal leukemia. N Engl J Med 1973; 289: 770-773.
68. Bender RA. Meningeal carcinomatosis. Treatment with intrathecal methotrexate. Oncology 1974; 30: 328-333.
69. Ettinger LJ, Chervinsky DS, Freeman AI, et al. Pharmacokinetics of methotrexate following intravenous and intraventricular administration in acute lymphocytic leukemia and non-Hodgkin's lymphoma. Cancer 1982; 50: 1676-1682.
70. Trump DL, Grossman SA, Thompson G, et al. Treatment of neoplastic meningitis with intraventricular thiotepa and methotrexate. Cancer Treat Rep 1982; 66: 1549-1551.
71. Hitchins RN, Bell DR, Woods RL, et al. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 1987; 5: 1655-1662.
72. Sause WT, Crowley J, Eyre HJ, et al. Whole brain irradiation and intrathecal methotrexate in the treatment of solid tumor leptomeningeal metastases: A southwest oncology group study. J Neurooncol 1988; 6:107-112.
73. Grochow LB, Grossman SA, Garrett S, et al. Pharmacokinetics of intraventricular thio-tepa (TT) in patients with meningeal carcinomatosis. Proc Am Soc Clin Oncol 1982; 1: 19.
74. Gutin PH, Weiss HD, Wiernik PH, et al. Intrathecal N, N′, N″- triethylenethiophosphoramide {thio- TEPA(NSC 6396)} in the treatment of malignant meningeal disease: Phase I-II study. Cancer 1976; 38: 1471-1475.
75. Grossman SA, Finkelstein DM, Ruckdeschchel JC, et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol, 1993; 11: 561-569.
76. Zimm S, Coffins JM, Miser J, et al. Cytosine arabinoside cerebrospinal fluid kinetics. Clin Pharmacol Ther 1984; 35: 826-830.
77. Hitchins RN, Bell DR, Woods RL, et al. A prospective randomized trial of single agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 1987; 5: 1655-1662.
78. Stewart DJ, Smith TL, Keating MJ, et al. Combined intraommaya methotrexate, cytosine arabinoside, hydrocortisone and thio-TEPA or meningeal involvement by malignancies. J Neurooncol 1985; 5: 315-322.
79. Giannone L, Greco FA, Hainsowrth JD. Combination intraventricular chemotherapy for meningeal neoplasia. J Clin Oncol 1986; 4: 68-73.
80. Glantz MJ, Cole BF, Recht L, et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer; is intrathecal chemotherapy necessary? J Clin Oncol 1998; 16: 1561-1567.
81. Chamberlain MC, Kormanik PA, Barba D. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 1997; 87: 694-699.
82. Trump DL, Grossman SA, Thompson G, et al. CSF infections complicating the management of neoplastic meningitis: Clinical features and results of therapy. Arch Intern Med 1982; 142: 583-586.
83. Bleyer WA, Drake JC, Chabner BA. Neurotoxicity and elevated cerebrospinal fluid methotrexate concentration in meningeal leukemia. N Engl J Med 1973; 289: 770-773.
84. Bleyer WA. Current status of intrathecal chemotherapy for human meningeal neoplasms. Natl Cancer Inst Monogr 1977; 46: 171-178.
85. Burch PA, Grossman SA. Spinal cord penetration of intrathecally administered cytosine arabinoside and methotrexate: A quantitative autoradiography study. JNCI 1988; 80(15): 1211-1216.
86. Grossman SA, Reinhard CS, Loats HL. The intracerebral penetration of intraventricularly administered methotrexate: A quantitative autoradiographic study. J Neurooncol 1989; 7: 319-323.
87. Gilbert MR, Harding BL, Grossman SA. Methotrexate neurotoxicity: In vitro studies using cerebellar expiants. Cancer Res 1989; 49: 2502-2505.
88. Grossman SA. NCCN clinical practice guidelines for the management of leptomeningeal métastases. Oncology, in press, 1999.
89. Blaney SM, Poplack DG. New cytotoxic drugs for intrathecal administration. Journal of Neuro-Oncology 1998; 38: 219-223.
90. Arndt CAS, Colvin M, Baus FM, et al. Intrathecal administration of 4-hydroperoxy-cyclophosphamide in rhesus monkey. Cancer Res 1987; 47: 5932-5934.
91. Fuchs HE, Archer GE, Colvin OM, et al. Activity of intrathecal 4-hydroperoxycyclophosphamide in a nude rat model of human neoplastic meningitis. Cancer Res 1990; 50: 1954-1959.
92. Blaney SM, Poplack DG. New cytotoxic drugs for intrathecal administration. Journal of Neuro-Oncology 1998; 38: 219-223.
93. Zimm S, Collins J, Curt G. et al. Cerebrospinal fluid pharmacokinetics of intraventricular and intravenous aziridinylbenzoquinone. Cancer Res 1984; 44: 1698-1701.
94. Berg SL, Balis FM, Zimm S, et al. Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies. J Clin Oncol 1992; 10: 143-148.
95. Blaney S, Cole D, Balis F, et al. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res 1993; 53: 725-727.
96. Blaney S, Cole D, Godwin, et al. Intrathecal administration of topotecan in nonhuman primates. Cancer Chemother Pharmacol 1995; 36: 121-124.
97. Huang T. and Howng SL (1997) Intrathecal ACNU against experimental leptomeningeal tumors. Kao-Hsiung I Hsueh Ko Hsueh Tsa Chih [Kaosiung Journal of Medical Sciences] 1997; 13(10): 626-30.
98. Tsuboi K, Hyodo A, Takada K and Nose T. Leukoencephalopathy associated with intra-arterial ACNU in patients with gliomas. Journal of Neuro-Oncology 1995; 23(3): 223-231.
99. Chamberlain MC, Khatibi S, Kim JC, et al. Treatment of leptomeningeal metastases with intraventricular administration of depot cytarabine (DTC 101): A phase I study. Arch Neurol 1993; 50: 261-264.
100. Chamberlain MC, Kormanik P, Howell SB, Kim S. Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. Arc Neurol 1995; 52: 912-917.
101. Kim S, Chatelut E, Kim JC, et al. Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol 1993; 11: 2186-2193.
102. Howell S. Personal communication, 1999.
103. Youle RJ. Immunotoxins for central nervous system malignancies. Cancer Biology 1996; 7: 65-70.
104. Myklebust AT, Godal A, Godstad O. Targeted therapy with immunotoxins in a nude rat nodel for leptomeningeal growth of human small cell lung cancer. Cancer Research 1994; 54: 2146-2150.
105. Hall WA, Myklebust MD, Godal A. et al. In vivo efficacy of intrathecal transferrin-psuedomonas exotoxin A immunotoxin against LOX melanoma. Neurosurgery 1994; 34: 649-655.
106. Pastan IH, Archer GE, McLendon RE et al. Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38] produces cures of carcinomatous meningitis in a rat model. Proceedings of The National Academy of Science USA 1995; 92: 2765-2679.
107. Laske DW, Muraszko KM, Oldfield EH, et al. Intraventricular immunotoxin for leptomeningeal neoplasia. Neurosurgery 1997; 41:1039-1051.
108. Papanastassiou V, Pizer BL, Chandler CL et al. Pharmacokinetics and dose estimates following intrathecal administration of 131-I-monoclonal antibodies for the treatment of central nervous system malignancies. Int J Radiat Oncol Biol Phys 1995; 31: 541-552.
109. Moseley RP, Oge K, Shafqat S, et al. HMFG1 antigen: A new marker for carcinomatous meningitis. Int J Cancer 1989; 44: 440-444.
110. Mosley RP, Davies AG, Richardson RM, et al. Intrathecal administration of 131-I-radiolabelled monoclonal antibody as a treatment of neoplastic meningitis. Br J Cancer 1990; 62: 637-642.
111. Mosely RP. Immunoreactivity pharmacokinetics and bone marrow dosimetry of intrathecal radioimminoconjugates. Int J Cancer 1992; 52: 38-43.
112. Bigner DD, Brown M, Coleman RE et al. Phase I studies of treatment of malignant glioma and neoplastic meningitis with 131-I-radiolabeled monoclonal antibodies anti-tenascin 81C#af and anti-chondroitin proteoglycan sulfate Mel-14F (ab')2 - A preliminary report. Journal of Neuro-Oncology 1995; 24: 109-122.
113. Coakham HB, Kemshead JT. Treatment of neoplastic meningitis by targeted radiation using 131-I labeled monoclonal antibodies. Results of responses and long term follow-up in 40 patients. Journal of Neuro-Oncology 1998; 38: 225-232.
114. Zalutsky MR, McLendon RE, Garg PK et al. Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate. Cancer Research 1994; 54: 4719-4725.
115. Zalutsky MR, Bigner DD. Radioimmunotherapy with alpha- particle emitting radioimmunoconjugates. Acta Oncologica 1996; 35: 373-379.
116. Ram Z, Walbridge S, Oshiro EM et al. Intrathecal gene therapy for malignant leptomeningeal neoplasia. Cancer Res 1994; 54: 2141-2145.
117. Vrionis FD, Wu J, Qi P, et al. Tumor cells expressing the herpes simplex virus thymidine kinase gene in the treatment of walker 256 meningeal neoplasia in rats. J Neurosurg 1996; 84: 250-257.
118. Viola JJ, Ram Z, Walbridge S, et al. Adenovirally mediated gene transfer into experimental solid brain tumors and leptomeningeal cancer cells. J Neurosurg 1995; 82: 70-76.
119. Vincent A, Esandi M, van Someren G, et al. Treatment of leptomeningeal metastases in a rat model using a recombinant adenovirus containing the HSV-tk gene. J Neurosurg 1996; 85: 648-654.
120. Rosenfeld MR, Bergman I, Schramm L et al. Adeno-associated viral vector gene transfer into leptomeningeal xenografts. Journal of Neuro-Oncology 1997; 34: 139-144.
121. Kramm CM, Chase M, Herrlinger U et al. Therapeutic efficacy and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Human Gene Therapy 1997; 8: 2057-2068.